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Typical 22q11.2 deletion syndrome appears to confer a reduced
risk of schwannoma
D. Gareth Evans1✉, Ludwine M. Messiaen2, William D. Foulkes3, Rachel E. A. Irving4, Alexandra J. Murray4, Cristina Perez-Becerril1,
Barbara Rivera5, Donna M. McDonald-McGinn6,7, David A. Stevenson8 and Miriam J. Smith 1
PURPOSE: The LZTR1 gene has been associated with schwannomatosis tumor predisposition and is located in a region that is
deleted in the great majority (89%) of patients with 22q11.2 deletion syndrome (22q11.2DS). Since it is known that approximately 1
in 500 people in the general population will develop a sporadic schwannoma and there are no reports of the occurrence of
schwannoma in 22q11.2DS, we investigated whether whole-gene deletion of LZTR1 occurs in schwannomatosis and assessed the
risk of schwannoma in 22q11.2DS.
METHODS: We assessed the genetic testing results for LZTR1-associated schwannomatosis and the clinical phenotypes of patients
with 22q11.2DS.
RESULTS: There were no reports of schwannoma in over 1,500 patients with 22q11.2DS. In addition, no patients meeting clinical
diagnostic criteria for schwannomatosis had a whole-gene deletion in LZTR1. Only 1 patient in 110 with an apparently sporadic
vestibular schwannoma had a constitutional whole-gene deletion of LZTR1.
CONCLUSION: People with a large 22q11.2 deletion may have a reduced risk of developing a schwannoma compared to the
general population.
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INTRODUCTION
Heterozygous loss-of-function pathogenic variants in LZTR1 are a
known cause of schwannoma predisposition1 and account for
around 30% of both inherited and sporadic cases of schwanno-
matosis.2 The mechanism of schwannoma formation resulting
from a germline pathogenic variant in LZTR1 on chromosome 22 is
more complex than the traditional two-hit hypothesis3 and is
thought to require biallelic loss of NF2 as well as LZTR1.4,5
Following the predisposing germline event (hit 1), a subsequent,
acquired loss of the unaffected copy of 22q deletes the remaining
copy of LZTR1 and also one copy of NF2 (a second event including
two genetic hits). The final (third) event is the additional
acquisition of a loss-of-function variant (usually of a single
nucleotide) in NF2.5 This three-event, four-hit mechanism is now
well established as the cause of schwannomas both through the
SMARCB1 and LZTR1 pathways. Whole-gene deletion and other
copy-number variants in SMARCB1 are typically linked to rhabdoid
tumor predisposition syndrome (RTPS) and have not been
reported to cause schwannomas.6 Typically, schwannomatosis-
associated SMARCB1 variants that cause around 40% of hereditary
and 10% of sporadic schwannomatosis are “hypomorphic” with
some presumed preserved function of the affected allele.6 This
preserved function appears to be sufficient to prevent develop-
ment of rhabdoid tumors in the critical first few years of life.
Typical LZTR1 variants that cause schwannomatosis are more likely
to be truncating variants, such as frameshift deletions and
nonsense variants that are predicted to lead to complete loss of
protein, while nontruncating variants are less common.2 However,
whole-gene deletions have not been reported in
schwannomatosis.
The LZTR1 gene is located within chromosome 22q11.2. This
region is known to be deleted in the majority of people with
22q11.2 deletion syndrome (22q11.2DS), which occurs in approxi-
mately 1 in 3–6,000 live births.7 The 22q11.2 deletions occur
between four low copy repeat regions, LCR22A, LCR22B, LCR22C,
and LCR22D, varying in size from approximately 700 kilobases to
three megabases. The LZTR1 gene is located within the
LCR22C–LCR22D region. The most common deletion is three
megabases, caused by nonallelic homologous recombination
(NAHR) between LCR22A and LCR22D. The major features of
22q11.2DS are immunodeficiency, palatal anomalies, hypopar-
athyroidism, and congenital heart disease (CHD). There are many
other possible associated features of this condition, such as
skeletal, renal, and gastrointestinal differences, autoimmune
disease, cognitive deficits, behavioral differences, and psychiatric
illness. However, schwannomas have not been reported in people
with this deletion and whole-gene deletions have not been
reported in LZTR1-associated schwannomatosis. We sought to
investigate the risk of schwannomas in 22q11.2 deletion
syndrome and the association with whole-gene deletion in
LZTR1-associated schwannomatosis.
MATERIALS AND METHODS
Two large genetic testing databases were interrogated to identify LZTR1
variants in individuals who presented with schwannomas. A total of 247
individuals were identified with an LZTR1 variant. Of these, 124 were
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identified through the Manchester Centre for Genomic Medicine and 123
were identified through the genetic testing service at Birmingham,
Alabama. This excluded class 3 variants with low likelihood of reclassifica-
tion to likely pathogenic. These samples were analyzed using a
combination of Sanger sequencing, and in-house next-generation panel
sequencing (including the NF2, SMARCB1, and LZTR1 genes). Copy number
was assessed by multiple ligation-dependent probe amplification (MLPA),
using probe sets P043-NF2, P258-B1, and P455 LZTR1, respectively (MRC-
Holland, Amsterdam, the Netherlands), or by microarray analysis using the
OGT CytoSure Constitutional v3 8x60k array or Illumina Infinium CytoSNP-
850K array.
To determine the number of schwannomas found in people with
22q11.2 deletion syndrome, 1,556 patients with known 22q11.2 deletion
syndrome were identified through the 22q and You Center at the
Children’s Hospital of Philadelphia. Loss of 22q11.2 was assessed in the
majority by microarray analysis and hospital records were assessed for
associated conditions. Of these patients, 322 were assessed by clinical
brain magnetic resonance image (MRI) due to a history of seizures/
abnormal neurologic exam and another 94 were assessed by brain MRI as
part of a research study. In addition, 94 were assessed by spine MRI due to
a suspicion of a tethered cord. Furthermore, a survey of the UK database of
22q11.2DS self-reported cases was conducted through social media and by
email through the Max Appeal charity.
RESULTS
We reviewed the genetic testing results for schwannoma
predisposition in over 1,000 cases from unrelated families in two
large genomic testing laboratories. In a total of 247 identified
LZTR1 variants, there were no single or multiple exon deletions,
and no whole-gene deletions, identified in patients fulfilling
schwannomatosis criteria. A denominator for schwannomatosis
was not known in Birmingham, Alabama. However, 116/425
(27.3%) of those meeting schwannomatosis criteria in Manchester
(100/400 unrelated families [25%]) had a variant in LZTR1
(excluding class 3 variants of uncertain significance). A further 8
individuals with an isolated schwannoma in Manchester had an
LZTR1 variant. This included 4/110 patients who presented with
sporadic vestibular schwannoma who were screened for LZTR1
variants. In this group, one of the four LZTR1 pathogenic variant
positive cases had a germline whole-gene deletion. Microarray
analysis indicated that the deletion extended to 942 kilobases,
between LCR22B-D domains (Fig. 1). The patient, who was in her
early 20s, had no features of 22q11.2DS. She had not had her
tumor removed, so further investigation of the mechanism of
schwannoma formation was not possible (it is normal procedure
to watch and wait and rescan a small vestibular schwannoma as
they may not need surgery or other treatment for many years).
Age of onset of first schwannoma was available on 122 patients
(range 3–78) and confirmed a median of 38 years (mean= 39.6)
with 24 aged <29 years.
We next assessed the known incidence of schwannoma in
22q11.2 deletion syndrome. It is known that the typical three
megabase deletion that accounts for 85% of cases includes
complete deletion of LZTR1.8 Yet no single case of schwannoma
appears in 3,054 reports of Di George syndrome on PubMed
(searches using the terms: Di George syndrome AND “schwan-
noma” and 22q11.2 deletion syndrome AND “schwannoma” were
carried out at https://pubmed.ncbi.nlm.nih.gov/?term=Di+George
+syndrome+&sort=date, 22 September 2020), nor in 3,031
reports of 22q11.2 deletion syndrome. We also assessed known
incidence in over 1,556 patients with known 22q11.2 deletion
syndrome evaluated in the 22q and You Center at the Children’s
Hospital of Philadelphia. Of those with microarray analysis, 1,046/
1,151 (89%) patients had a deletion involving LZTR1 (Table 1). A
further 405 individuals had only fluorescence in situ hybridization
(FISH) analysis. No cases of schwannoma have been observed
in this cohort, despite over 51% of these patients being adults. In
addition, a total of 418 of these patients were assessed by brain
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b Sporadic VS deletion
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Fig. 1 Schematic diagram of chr 22q11.2 indicating low copy repeat regions. Solid gray bars indicate (a) the common 3-mb deletion region
seen in 22q11.2DS (upper bar), (b) the deleted region in the LZTR1-associated vestibular schwannoma patient with a whole-gene deletion
(middle bar), and (c) the approximate breakpoints in tumors from two unrelated LZTR1-associated schwannomatosis patients (lower bar).
Table 1. 22q11.2 cases from the 22q and You Center at the Children’s Hospital of Philadelphia registry and from the UK charity Max Appeal.
Patient age (years) LZTR1-deleted LZTR1 nondeleted FISH/unknown UK Max Appeala
n % (All) % (Known) n % (All) % (Known) n % (All) % (Known) n % (All)
0 to 18 545 72% 88% 75 10% 12% 132 18% – 1,013 60%
19 to 29 298 59% 91% 31 6% 9% 175 35% – 292 17%
30 to 49 134 65% 94% 9 4% 6% 64 31% – 220 13%
50+ 24 67% 86% 4 11% 14% 8 22% – 170 10%
Deceased/unknown 25 44% 81% 6 11% 19% 26 46% –
Total 1,026 66% 89% 125 8% 11% 405 26% – 1,695
FISH fluorescence in situ hybridization.
aUK Max Appeal cases where self-reported and presence or absence of deletion of LZTR1 was unknown. Furthermore, no record assessment or confirmation
of the 22q11.2 deletion was possible. Survey was carried out by Twitter, Facebook, and email between 1 and 30 October 2020.
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MRI and 94 were assessed by spine MRI and no schwannomas
were detected.
A survey of 1,695 UK self-reported individuals with 22q11.2DS
and their families through the family support organization, Max
Appeal, did not identify any cases of schwannoma or nerve sheath
tumor, although several likely schwannomas were identified in
siblings and parents without known 22q11.2DS.
We also assessed the rate of probable LZTR1 loss-of-function
variants in gnomAD data (https://gnomad.broadinstitute.org/
transcript/ENST00000215739?dataset=gnomad_r2_1; 20 January
2021). There were 465 from a mean of 112,096 individuals (~1 in
241) with a nonsense, frameshift, or canonical splice region variant
(excluding low confidence calls). This means that if the effect of a
whole-gene deletion were the same as a loss-of-function point
variant, then, due to the 1 in 3–6,000 frequency of 22q11.2DS, we
should expect to find one 22q11.2 deletion for every 12 to 25
LZTR1-associated schwannomatosis diagnoses. Therefore, in our
cohort of 247 LZTR1-associated schwannomatosis patients, we
should have found a minimum of ten 22q11.2 deletions, but none
were found.
DISCUSSION
In the general population, 1 in 500 people will develop a sporadic
schwannoma (1 in 1,000 will develop a vestibular schwannoma
and 1 in 1,000 will develop a nonvestibular schwannoma).9 While
the majority of heritable predisposition to schwannomas is known
to be associated with NF2 germline variants, a proportion of these
have also been associated with LZTR1 variants.1,2 In our review of
1,556 people with proven 22q11.2DS (89% with LZTR1 deletion)
none had a schwannoma. This finding was confirmed by brain MRI
in 418 people, and by spine MRI in 94 people, in this group.
Assuming a similar proportion in the self-reported unconfirmed
UK based survey of 22q11.2DS, a further 1,508 are likely also to
have had an LZTR1 deletion. This would mean that close to 3,000
people with LZTR1-deleted 22q11.2DS were included in our
analysis. Although many of these patients are still young, a large
number would have been expected to have developed schwan-
nomas if the risks were similar to typical LZTR1 loss-of-function
variants, since the median age at onset in people with a
pathogenic LZTR1 variant is 38 years in our cohort and 20%
developed symptomatic tumors below the age of 29 (~85% of the
22q11.2DS cohort is below this age). It would also be reasonable
to expect to have seen at least one by chance, i.e., population risk.
However, life expectancy is reduced in 22q11.2DS and the
presence of acute and life-threatening complications (such as
CHD, hypoparathyroidism, psychosis, cervical spine anomaly)
limits our current assessment.
The absence of reported schwannoma in the literature and in
two large series of patients with 22q11.2DS suggests that the
typical large deletion at 22q11.2, including LZTR1, is not a risk
factor for schwannoma. While whole-gene deletions and single
and multiple exon deletions occur as a relatively frequent
pathogenic variant type in tumor predisposition syndromes,
whole-gene deletions are not normally associated with loss of
heterozygosity (LOH) as the second loss-of-function event for that
gene.10 This does not negate the potential for biallelic loss of
function; however, the second hit is nearly always a single-
nucleotide pathogenic variant in the wild type allele. In the case of
LZTR1, a single-nucleotide pathogenic variant as a second hit
would not lead to loss of NF2 on the same allele and would almost
certainly not advance schwannoma formation. Alu repeats in the
deleted region lead to limited mechanisms of loss by recombina-
tion on that allele, leaving only the option of biallelic NF2 single-
nucleotide pathogenic variants, which occur as the cause in <30%
of sporadic vestibular schwannomas with both hits identified.11 It
is possible that this could have occurred in the single case we
observed with a large 22q11.2 deletion and a schwannoma, or the
tumor could have occurred as a chance association through
biallelic single-nucleotide pathogenic variants within the NF2
gene.
Assuming that somatic loss of the normal copy of 22q is
mechanistically still possible in patients with 22q11.2DS, it is
indeed possible that homozygous deletion of such a large region,
involving multiple genes, might be cell lethal, thus preventing
tumor development. Some support for this theory comes from
analysis of copy-number alterations found in cancer cell lines, e.g.,
using the copy-number analysis (CONAN) database (http://www.
sanger.ac.uk/cgi-bin/genetics/CGP/conan/search.cgi) available
through the Wellcome Trust Sanger Institute Cancer Genome
Project (accessed 11 June 2020).11 It also remains possible that a
complete absence of LZTR1 protein due to deletion does not
provide the same pathogenic effect as a partially functional
protein.12 In addition, the normal mechanism of sporadic
schwannoma formation with a point variant and LOH of NF2
would only be possible if the single-nucleotide pathogenic variant
occurred in trans with the 22q11.2 deletion, further reducing the
chances of even a sporadic schwannoma. It is therefore possible
that if loss of both copies of the whole wild type 22q11.2 allele is
cell lethal, then 22q11.2 deletion syndrome patients may have a
reduced risk of schwannoma as well as other 22q mediated
tumors such as meningioma. However, only further follow up of
an even larger series of patients with a proven chromosome
22q11.2 deletion inclusive of LZTR1 into older age will assess the
validity of this possibility.
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